This study aimed at evaluating the behaviour and understanding the diagnostic value of the carcinoembryonic antigen (CEA) in bitches with mammary carcinoma as a tool for monitoring and prognosis of canine cancer patients. Serum samples from 77 bitches were divided into four groups, G1 (n = 21), control group (healthy/neoplasia free bitches); G2 (n = 31), bitches with non‐metastatic mammary carcinoma less than 3 cm; G3 (n = 12), bitches with non‐metastatic mammary carcinoma greater than 3 cm; and, G4 (n = 13) bitches with mammary carcinoma and lymph node metastasis. The marker was dosed once in G1, whereas in G2, G3 and G4, CEA levels were determined before (M0) and 15 days after (M1) mastectomy, using the ELISA kit for humans while reading used ELISYS ONE human. A group of 11 bitches was followed up 45 days after mastectomy (M2). The results for the concentration of markers in blood serum samples at the evaluated times and their relationship with neoplasia biological behaviour and observed clinicopathological changes were evaluated by the Tukey test at 5% significance. The ROC curve was established to find the cut‐off value and calculate the test sensitivity and specificity, the multivariate matching analysis was performed to confirm the association between CEA values and clinicopathological variables. CEA values increased significantly in bitches with mammary carcinoma, metastatic tumours with a diameter larger than 3.0 cm and high grade, compared with healthy ones. In addition, mastectomy reduced the CEA concentration in the blood (P < .05) whereas high CEA levels were associated with unfavourable prognostic factors (P < .05). The biomarker presented good diagnostic value, especially for more aggressive tumours. In conclusion, CEA serum concentrations allowed to follow efficiently the evolution of mammary tumours in bitches, since CEA values increased in bitches with mammary gland tumour and decreased after mastectomy while correlating with prognostic factors such as tumour size, nodal metastasis and histological grade. Further studies are still needed to confirm its diagnostic value for follow‐up of relapse and early metastasis.

中文翻译：

---

癌胚抗原在母犬乳腺肿瘤中的临床价值。

这项研究旨在评估行为和了解母乳癌中的癌胚抗原（CEA）作为监测和预测犬癌患者的工具的诊断价值。将77只母犬的血清样本分为四组，G1组（n = 21），对照组（健康/无石斑母犬）。G2（n = 31），雌性非转移性乳腺癌小于3 cm；G3（n = 12），母犬非转移性乳腺癌大于3 cm；G4（n = 13）个母犬，有乳腺癌和淋巴结转移。标记物在G1中给药一次，而在G2，G3和G4中，使用人类ELISA试剂盒同时读取使用过的ELISYS ONE人，在乳腺切除术之前（M0）和之后（M1）15天确定CEA水平。乳房切除术（M2）后45天对11个母犬进行了随访。通过Tukey检验以5％的显着性评估评估时间时血清样品中标志物浓度的结果及其与瘤形成生物学行为和观察到的临床病理变化的关系。建立ROC曲线以找到临界值并计算测试灵敏度和特异性，进行多变量匹配分析以确认CEA值与临床病理变量之间的关联。与健康的母乳相比，在患有乳癌，直径大于3.0 cm的转移性肿瘤和高级别母犬中，CEA值显着增加。此外，乳房切除术降低了血液中CEA的浓度（建立ROC曲线以找到临界值并计算测试灵敏度和特异性，进行多变量匹配分析以确认CEA值与临床病理变量之间的关联。与健康的母乳相比，在患有乳癌，直径大于3.0 cm的转移性肿瘤和高级别母犬中，CEA值显着增加。此外，乳房切除术降低了血液中CEA的浓度（建立ROC曲线以找到临界值并计算测试灵敏度和特异性，进行多变量匹配分析以确认CEA值与临床病理变量之间的关联。与健康的母乳相比，在患有乳癌，直径大于3.0 cm的转移性肿瘤和高级别母犬中，CEA值显着增加。此外，乳房切除术降低了血液中CEA的浓度（与健康的相比。此外，乳房切除术降低了血液中CEA的浓度（与健康的相比。此外，乳房切除术降低了血液中CEA的浓度（P  <.05），而高CEA水平与不良预后因素相关（P  <.05）。该生物标志物具有良好的诊断价值，尤其是对于更具侵略性的肿瘤。总之，CEA血清浓度可以有效地跟踪母犬中乳腺肿瘤的进展，因为CEA值在具有乳腺肿瘤的母犬中升高，而在乳房切除术后降低，同时与肿瘤大小，淋巴结转移和组织学分级等预后因素相关。仍需要进一步的研究以确认其对复发和早期转移的随访的诊断价值。